Patents by Inventor Jacob P. Sizemore

Jacob P. Sizemore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
    Publication number: 20220220093
    Abstract: Provided herein are amorphous and crystalline hemisulfate salt forms of the formula. Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 14, 2022
    Inventors: Jacob P. Sizemore, Liting Guo, Mahmoud Mirmehrabi, Yeqing Su
  • Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
    Patent number: 11254652
    Abstract: Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 22, 2022
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Jacob P. Sizemore, Liting Guo, Mahmoud Mirmehrabi, Yeqing Su
  • CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL)PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE
    Publication number: 20200277279
    Abstract: Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
    Type: Application
    Filed: November 21, 2018
    Publication date: September 3, 2020
    Inventors: Jacob P. Sizemore, Liting Guo, Mahmoud Mirmehrabi, Yeqing Su
  • Crystalline form of a ?-lactamase inhibitor
    Patent number: 9120795
    Abstract: This disclosure provides compositions containing solid forms of sodium (2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate, and methods of manufacturing and using these compositions.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 1, 2015
    Assignee: Cubist Pharmaceuticals, Inc.
    Inventors: You Seok Hwang, Jian-Qiao Gu, Akash Jain, Sudhakar Garad, Jacob P. Sizemore
  • CRYSTALLINE FORM OF A BETA-LACTAMASE INHIBITOR
    Publication number: 20140275001
    Abstract: This disclosure provides compositions containing solid forms of sodium (2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate, and methods of manufacturing and using these compositions.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Inventors: You Seok Hwang, Jian-Qiao Gu, Akash Jain, Sudhakar Garad, Jacob P. Sizemore